BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.79 Million EUR | -199.91% |
| 2022 | -2.25 Million EUR | 80.8% |
| 2021 | -864 Thousand EUR | 18.45% |
| 2020 | -14.83 Million EUR | -63.21% |
| 2019 | -6.69 Million EUR | 32.26% |
| 2018 | -13.13 Million EUR | -13.09% |
| 2017 | -11.65 Million EUR | 4.28% |
| 2016 | -12.16 Million EUR | -1.27% |
| 2015 | -13.06 Million EUR | -132.74% |
| 2014 | -5.18 Million EUR | -47.94% |
| 2013 | -3.5 Million EUR | -6.41% |
| 2012 | -3.15 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -180.5 Thousand EUR | 0.0% |
| 2024 Q1 | -180.5 Thousand EUR | 87.95% |
| 2023 FY | - EUR | -224.27% |
| 2023 Q1 | -1.9 Million EUR | -112.89% |
| 2023 Q2 | -4.16 Million EUR | -119.21% |
| 2023 Q3 | -1.49 Million EUR | 64.03% |
| 2023 Q4 | -1.49 Million EUR | 0.0% |
| 2022 Q4 | -892.5 Thousand EUR | 0.0% |
| 2022 FY | - EUR | 80.8% |
| 2022 Q3 | -892.5 Thousand EUR | 78.97% |
| 2022 Q2 | -4.24 Million EUR | 0.0% |
| 2021 Q4 | -7.2 Million EUR | 0.0% |
| 2021 FY | - EUR | 18.45% |
| 2021 Q2 | -6.43 Million EUR | 0.0% |
| 2020 Q4 | -7.29 Million EUR | 0.0% |
| 2020 FY | - EUR | -63.21% |
| 2020 Q2 | -9.78 Million EUR | 0.0% |
| 2019 FY | - EUR | 32.26% |
| 2019 Q2 | -6.72 Million EUR | 0.0% |
| 2019 Q4 | -7.01 Million EUR | 0.0% |
| 2018 Q4 | -7.29 Million EUR | 0.0% |
| 2018 FY | - EUR | -13.09% |
| 2017 FY | - EUR | 4.28% |
| 2016 FY | - EUR | -1.27% |
| 2015 FY | - EUR | -132.74% |
| 2014 Q3 | -953 Thousand EUR | 0.0% |
| 2014 FY | - EUR | -47.94% |
| 2014 Q4 | -1.79 Million EUR | -88.04% |
| 2013 Q4 | -1.17 Million EUR | 0.0% |
| 2013 FY | - EUR | -6.41% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -106.565% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 94.898% |
| Adocia SA | -22.73 Million EUR | 70.104% |
| Aelis Farma SA | -6.34 Million EUR | -7.074% |
| Biophytis S.A. | -13.8 Million EUR | 50.768% |
| Advicenne S.A. | -6.24 Million EUR | -8.84% |
| genOway Société anonyme | 6.35 Million EUR | 207.011% |
| IntegraGen SA | -52.5 Thousand EUR | -12844.022% |
| Medesis Pharma S.A. | -3.84 Million EUR | -76.754% |
| Neovacs S.A. | -8.44 Million EUR | 19.57% |
| NFL Biosciences SA | -4.04 Million EUR | -67.831% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 9469.916% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -136.508% |
| Sensorion SA | -22.31 Million EUR | 69.544% |
| Theranexus Société Anonyme | -7.38 Million EUR | 8.003% |
| TME Pharma N.V. | -5.07 Million EUR | -33.991% |
| Valbiotis SA | -6.95 Million EUR | 2.286% |
| TheraVet SA | -517.33 Thousand EUR | -1213.653% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 64.073% |
| argenx SE | -199.5 Million EUR | 96.594% |
| Celyad Oncology SA | -7.76 Million EUR | 12.457% |
| DBV Technologies S.A. | -79.53 Million EUR | 91.455% |
| Galapagos NV | 51.03 Million EUR | 113.316% |
| Genfit S.A. | -28.05 Million EUR | 75.773% |
| GeNeuro SA | -14.31 Million EUR | 52.534% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 54.633% |
| Innate Pharma S.A. | -7.57 Million EUR | 10.319% |
| Inventiva S.A. | -101.84 Million EUR | 93.327% |
| MaaT Pharma SA | -19.74 Million EUR | 65.572% |
| MedinCell S.A. | -20.04 Million EUR | 66.098% |
| Nanobiotix S.A. | -34.01 Million EUR | 80.023% |
| Onward Medical N.V. | -35.23 Million EUR | 80.712% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -53.292% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 70.79% |
| Oxurion NV | -16.72 Million EUR | 59.376% |
| Pharming Group N.V. | 4.98 Million EUR | 236.439% |
| Poxel S.A. | -12.17 Million EUR | 44.199% |
| GenSight Biologics S.A. | -21.73 Million EUR | 68.725% |
| Transgene SA | -27.02 Million EUR | 74.852% |
| Financière de Tubize SA | 184.57 Thousand EUR | 3782.052% |
| UCB SA | 1.26 Billion EUR | 100.536% |
| Valneva SE | -64.51 Million EUR | 89.466% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 76.031% |